Merck & Co., Inc., Rahway, NJ, USA (United States)
In research, Merck & Co., Inc., Rahway, NJ, USA (United States) stands highest in Medicine (#639 of 10,443 worldwide), Health Sciences (#872 of 11,982 worldwide) and Physical Sciences (#1,156 of 12,888 worldwide), 2022–2025. Relative to its size it is most specialised in Pharmaceutical Science, Spectroscopy and Statistics and Probability — Pharmaceutical Science is 12.1× its share of world research.
- World rank, 2022–2025
- #1,130 of 28,054 · #515 all time
- Rank in United States
- #192 of 4,192
- Research works
- 18k ▲ 12% vs 2013–17
- Citations
- 742k 42.1 per fractional work
- Top-10% rate
- 19.3% record average 16.5%
- Open access
- 32% world 28%
What is Merck & Co., Inc., Rahway, NJ, USA (United States) known for in research?
The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works | All time |
|---|---|---|---|---|---|
| MedicineField | #639 of 10,443 | 18.6% | 763 | #250 | |
| Health SciencesDomain | #872 of 11,982 | 18.6% | 800 | #315 | |
| Physical SciencesDomain | #1,156 of 12,888 | 22.4% | 389 | #1043 | |
| Organic ChemistrySubfield | #60 of 615 | 35.4% | 90 | #90 | |
| ChemistryField | #133 of 1,330 | 27.0% | 169 | #196 | |
| Life SciencesDomain | #957 of 7,800 | 18.6% | 450 | #222 | |
| EpidemiologySubfield | #239 of 976 | 25.3% | 140 | #233 | |
| Biochemistry, Genetics and Molecular BiologyField | #887 of 3,579 | 18.0% | 301 | #241 | |
| OncologySubfield | #246 of 772 | 18.9% | 130 | #95 | |
| Molecular BiologySubfield | #711 of 2,175 | 18.9% | 204 | #205 |
Each strip is that field’s whole ranked pool, with the notch where Merck & Co., Inc., Rahway, NJ, USA (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Which of those standings moved
The same fields on both windows: where it stood over the whole record, and where it stands in 2022–2025. The distance is the story, and it is the one thing the two rank columns above cannot show.
- Medicine#250 #639
- Health Sciences#315 #872
- Physical Sciences#1,043 #1,156
- Organic Chemistry#90 #60
- Chemistry#196 #133
- Life Sciences#222 #957
- Epidemiology#233 #239
- Biochemistry, Genetics and Molecular Biology#241 #887
- Oncology#95 #246
- Molecular Biology#205 #711
A dot further right is a better standing. Fields it was not ranked in over the whole record are left out.
What does Merck & Co., Inc., Rahway, NJ, USA (United States) specialise in?
Where its research is concentrated relative to its size: Pharmaceutical Science takes 12.1× the share of its output that it takes of world research.
- Pharmaceutical ScienceSubfield · 22.7 works12×
- SpectroscopySubfield · 43.4 works11×
- Statistics and ProbabilitySubfield · 35.0 works9.3×
- Organic ChemistrySubfield · 89.7 works6.8×
- OncologySubfield · 129.7 works6.6×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Chemistry, 6.2×. Every wedge is a field page.
- Chemistry 6.2×
- Pharmacology, Toxicology and Pharmaceutics 5.2×
- Immunology and Microbiology 4.6×
- Biochemistry, Genetics and Molecular Biology 3.2×
- Medicine 2.3×
- Veterinary 1.9×
- Mathematics 1.9×
- Economics, Econometrics and Finance 1.6×
- Decision Sciences 0.8×
- Health Professions 0.7×
- Chemical Engineering 0.6×
- Neuroscience 0.5×
- Materials Science 0.5×
- Computer Science 0.3×
- Engineering 0.3×
- Agricultural and Biological Sciences 0.3×
- Environmental Science 0.3×
- Energy 0.2×
- Nursing 0.2×
- Social Sciences 0.1×
- Psychology 0.1×
- Physics and Astronomy 0.1×
- Business, Management and Accounting 0.1×
- Dentistry 0.1×
- Arts and Humanities 0.0×
Who are the top researchers at Merck & Co., Inc., Rahway, NJ, USA (United States)?
Ranked on the composite score, Robert P. Sheridan, David E. Moller and Irwin Singer lead among researchers whose main affiliation is Merck & Co., Inc., Rahway, NJ, USA (United States).
- 1 Robert P. Sheridan United States · #29,619 worldwide 851 citations · 35 works
- 2 David E. Moller United States · #51,034 worldwide 351 citations · 38 works
- 3 Irwin Singer United States · #51,152 worldwide 395 citations · 32 works
- 4 Eric H. Rubin United States · #51,737 worldwide 332 citations · 35 works
- 5 Rodolfo F. Perini United States · #53,153 worldwide 510 citations · 29 works
- 6 Vassiliki Karantza United States · #54,075 worldwide 496 citations · 29 works
- 7 Keaven M. Anderson United States · #58,850 worldwide 631 citations · 27 works
- 8 Richard A. F. Dixon United States · #60,128 worldwide 316 citations · 35 works
- 9 Robert W. Egan United States · #61,962 worldwide 282 citations · 30 works
- 10 Mark J. DiNubile United States · #68,653 worldwide 465 citations · 27 works
Which keywords describe research at Merck & Co., Inc., Rahway, NJ, USA (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Epidemiology, Monoclonal Antibodies, Chemotherapy, Therapeutic Antibodies, Tumor Microenvironment, Glycosylation, Immunogenicity and Biopharmaceuticals.
- Cancer Incidence
- Health Utility Measures
- Fc Receptors
- Antibody Engineering
- Pneumococcal Conjugate Vaccine
- Respiratory Infections
- Human Papillomavirus
- Vaccine Development
- Stability
- PD-1 and PD-L1
- Protein Aggregation
- Targeted Therapy
- Pathogenesis
- Medicinal Chemistry
- Biomarkers
- Immunogenicity
- Immunotherapy
- Clinical Practice Guidelines
- Therapeutic Antibodies
- Monoclonal Antibodies
- Epidemiology
- Chemotherapy
- Tumor Microenvironment
- Clinical Trials
- Glycosylation
- Biopharmaceuticals
- Vaccine
- Antimicrobial Resistance
- Immune Response
- Recombinant Proteins
- Immune Checkpoint Blockade
- Chromatography
- Drug Discovery
- Treatment Guidelines
- Vaccination
- Community-Acquired Pneumonia
- Monoclonal Antibody
- Economic Evaluation
- Cost-effectiveness Analysis
- Molecular Characterization
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology215▲ 3.1×90 topics
- Monoclonal Antibodies82▲ 52×3 topics
- Chemotherapy79▲ 6.4×21 topics
- Therapeutic Antibodies70▲ 57×2 topics
- Tumor Microenvironment61▲ 7.8×8 topics
- Clinical Practice Guidelines60▲ 6.3×13 topics
- Clinical Trials58▲ 4.9×14 topics
- Immunotherapy57▲ 4.5×18 topics
- Glycosylation56▲ 28×3 topics
- Immunogenicity55▲ 72×3 topics
- Biopharmaceuticals54▲ 60×3 topics
- Biomarkers54▲ 4.5×18 topics
- Vaccine54▲ 7.5×10 topics
- Medicinal Chemistry49▲ 10×12 topics
- Antimicrobial Resistance48▲ 14×9 topics
- Pathogenesis46▲ 5.1×19 topics
- Immune Response45▲ 4.5×18 topics
- Targeted Therapy44▲ 11×5 topics
- Recombinant Proteins42▲ 76×2 topics
- Protein Aggregation40▲ 44×2 topics
- Immune Checkpoint Blockade40▲ 21×1 topic
- PD-1 and PD-L140▲ 21×1 topic
- Chromatography40▲ 152×1 topic
- Stability40▲ 10.0×1 topic
- Drug Discovery39▲ 10×8 topics
- Vaccine Development38▲ 8.4×8 topics
- Treatment Guidelines34▲ 8.9×5 topics
- Human Papillomavirus32▲ 15×3 topics
- Vaccination30▲ 23×2 topics
- Respiratory Infections30▲ 15×3 topics
- Community-Acquired Pneumonia30▲ 51×1 topic
- Pneumococcal Conjugate Vaccine30▲ 51×1 topic
- Monoclonal Antibody30▲ 32×2 topics
- Antibody Engineering29▲ 31×1 topic
- Economic Evaluation29▲ 14×2 topics
- Fc Receptors29▲ 31×1 topic
- Cost-effectiveness Analysis29▲ 20×1 topic
- Health Utility Measures29▲ 20×1 topic
- Molecular Characterization29▲ 9.2×6 topics
- Cancer Incidence29▲ 12×4 topics
Which research topics does Merck & Co., Inc., Rahway, NJ, USA (United States) publish most on?
By volume in 2022–2025: Cancer Immunotherapy and Biomarkers, Protein purification and stability, Pneumonia and Respiratory Infections and Monoclonal and Polyclonal Antibodies Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Immunotherapy and Biomarkers Oncology 40 works
- 2 Protein purification and stability Molecular Biology 40 works
- 3 Pneumonia and Respiratory Infections Epidemiology 30 works
- 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 29 works
- 5 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 29 works
- 6 Respiratory viral infections research Epidemiology 26 works
- 7 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 22 works
- 8 Vaccine Coverage and Hesitancy Health 22 works
- 9 Analytical Chemistry and Chromatography Spectroscopy 22 works
- 10 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 22 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Merck & Co., Inc., Rahway, NJ, USA (United States)'s research output changed?
Output in 2018–2022 was 12% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Rahway
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.